Medivir AB Has Initiated a Phase I Clinical Trial With Its Cathepsin K inhibitor MIV-711

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Medivir AB (OMX:MVIR), a research-based pharmaceutical company focused on infectious diseases, announced today that a phase I clinical trial has been initiated with its investigational drug, MIV-711, a cathepsin K inhibitor for the treatment of bone disorders characterized by excessive bone resorption such as osteoporosis, osteoarthritis and bone metastases.

Back to news